Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Beginning Cash Position : $38.80 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Beginning Cash Position?

Freeline Therapeutics Holdings's Beginning Cash Position for the quarter that ended in Sep. 2023 was $38.80 Mil.

Freeline Therapeutics Holdings's quarterly Beginning Cash Position increased from Mar. 2023 ($48.91 Mil) to Jun. 2023 ($55.42 Mil) but then declined from Jun. 2023 ($55.42 Mil) to Sep. 2023 ($38.80 Mil).

Freeline Therapeutics Holdings's annual Beginning Cash Position increased from Dec. 2020 ($74.57 Mil) to Dec. 2021 ($231.58 Mil) but then declined from Dec. 2021 ($231.58 Mil) to Dec. 2022 ($118.76 Mil).

Freeline Therapeutics Holdings Beginning Cash Position Historical Data

The historical data trend for Freeline Therapeutics Holdings's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Beginning Cash Position Chart

Freeline Therapeutics Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Beginning Cash Position

8.54

16.34

74.57

231.58

118.76

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Beginning Cash Position	Get a 7-Day Free Trial													91.29	66.76	48.91	55.42	38.80

Freeline Therapeutics Holdings Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Freeline Therapeutics Holdings Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP

Website

https://www.freeline.life

Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.